"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Cardiogenic shock is associated with poor clinical outcomes. There is a paucity of prospective data examining the efficacy and safety of different inotropic agents in patients with cardiogenic shock ...

In patients with rapidly deteriorating or severe cardiogenic shock, immediate use of extracorporeal membrane oxygenation (ECMO) does not improve outcomes over an initially conservative strategy with ...

A scarcity of dobutamine is starting to hit home for cardiologists, surgeons, and patients around the United States, catching some hospitals off guard despite warnings for months that supplies were ...

Persistent pulmonary hypertension of the newborn (PPHN) is a condition caused by a failure in the systemic and pulmonary circulation to convert from the antenatal circulation pattern to the normal ...

Clinical question: Is there a benefit to selecting milrinone over dobutamine for inotropic support in patients with cardiogenic shock? Background: Inotropes, particularly milrinone and dobutamine, are ...

Hyloris Pharmaceuticals SA, a specialty biopharma company, has acquired the global rights from the Baker Heart and Diabetes Institute (the Baker Institute), Melbourne, Australia, to CRD-102 (and ...

Targeting orphan, late-stage heart failure indication with high unmet medical needs Liège, Belgium – 8 October 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company ...

Hyloris Pharmaceuticals SA announces that it has acquired the global rights from the Baker Heart and Diabetes Institute, Melbourne, Australia, to CRD-102, a novel, clinical-stage, extended-release ...

Department of Emergency Medicine, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China Purpose: To determine whether inotrope administration is associated with increased ...